SUMMARY The possibility that the mode of action of sulphasalazine and its active metabolite 5-amino-salicylic acid (5ASA) involves modification of toxic oxygen metabolite production by neutrophils has been investigated by measuring the effect of these drugs on luminol-dependent chemiluminescence, superoxide release and oxygen consumption by stimulated neutrophils in vitro. 5ASA, and to a lesser extent sulphasalazine, had profound inhibitory effects on the luminol dependent chemiluminescent response of neutrophils stimulated with formyl-methionyl-leucylphenylalanine (1 [tM)+cytochalasin B (5 [igIml). A concentration of 50 ,tM 5ASA or sulphasalazine produced 93.8 (2-3)% and 65.7 (3.7)% inhibition of control responses respectively. The concentration of 5ASA and sulphasalazine producing 50% inhibition of chemiluminescence were 3-6 (1.8) [1M and 16.5 (6) FM respectively. Both drugs had little effect on the chemiluminescent response of neutrophils stimulated with phorbol myristate acetate (1 [ig/ml), producing only 11.4 (3.9)% and 34 (7)% inhibition respectively, at a concentration of 50 FM. Superoxide release from fMLP+CB stimulated neutrophils was also inhibited slightly by 5ASA (50 [tM) by 35-6% and by sulphasalazine (50 FM) by 7.9%. Similarly, there was little inhibition in the rate of oxygen consumption by fMLP+ CB stimulated neutrophils by either 5ASA or sulphasalazine at concentrations which produced near total abolition of luminol dependent chemiluminescence. These results show that sulphasalazine and 5ASA inhibit the reaction of toxic metabolites produced by stimulated neutrophils with luminol, without inhibition of the oxidase system producing these metabolites. The site of action of these drugs on neutrophils in vitro is thus extracellular, by scavenging a released metabolite, probably hypochlorite. This has important implications for their mode of action in vivo in inflammatory bowel disease.
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The beneficial effects of sulphasalazine on ulcerative colitis were first noted in the 1940s. ' Sulphasalazine is broken down in the colon by enteric bacteria into sulphapyridine and 5-amino-salicylic acid (5ASA).2
The active metabolite of SAL is 5ASA4 which has recently been used in the treatment of ulcerative colitis, being delivered to the colon in a pH sensitive coated capsule.' remains uncertain. Both Superoxide production by stimulated neutrophils was measured by reduction of cytochrome C.' One millilitre aliquots of neutrophil suspension (1x 10" neutrophils) were placed in plastic cuvettes (1 cm light path), to which was added cytochrome C type 111 (Sigma Chemical Co., Poole, Dorset) to a final concentration of 50 FM. Sulphasalazine or 5ASA, dissolved in DMSO, were added to the neutrophils (final concentration of sulphasalazine and 5ASA, 50 FtM; DMSO 0(15% v/v). Cells were stimulated with fMLP (1 tM) plus CB (5 Fg/ml). Reduction of cytochrome C was measured by absorbance at 550 nm in a PYE SP30 UV spectrophotometer, against a blank cuvette containing a similar volume of neutrophil suspension, and similar concentrations of cytochrome C, fMLP+CB and 300 units superoxide dismutase (Sigma Chemical Co.). Superoxide production was calculated from the rate of change of absorbance using Beer-Lamberts law, with the extinction coefficient E,25(=21X104/M/cm.
Each experiment was performed in triplicate using neutrophils from five different subjects.
OXYGFN CONSUMPTION
Oxygen consumption was measured using a Clark electrode in a purpose built chamber, maintained at 37°C." The polarising voltage of the electrode was maintained at 0(6 V and the output of the electrode was measured with a purpose built nano-ammeter and a chart recorder. The apparatus was calibrated by assuming that the concentration of oxygen dissolved in HEPES buffered Krebs medium at 37°C was 210 iM."' 15 X 107 neutrophils, suspended in 2 ml HEPES buffered Krebs medium, were placed in the specimen chamber, and allowed to reach steady state resting oxygen consumption.
Neutrophils were stimulated by adding FMLP (final concentration, 1 FM) and CB (final concentration 5 tg/ml). Experiments were performed in triplicate on neutrophils from five different subjects.
Results

INHIBIIION OF I UMINOI DEPEND1INI
CHEI MII UMINI`SC1 NCE Both sulphasalazine and 5ASA inhibited the burst of chemiluminescence produced by neutrophils when stimulated by fMLP+CB. This inhibition was characterised by a decrease in peak chemilumines-Effect ofsulphasalazine and its active metabolite, 5-amino-salicylic acid cence, without a decrease in the rate of rise, or increase in the lag time between stimulation and onset of response (Fig. Ia) . 5ASA was the more potent, 50 FtM producing 93-8 (2-3)% inhibition of the control chemiluminescent response (mean (SE), n=12, p=0.01 Wilcoxon's rank-sum test on paired data), whereas sulphasalazine at a similar concentration, produced 65-7 (3-7)% inhibition (n=9, p=O.Ol Wilcoxon's rank-sum test). The concentration of sulphasalazine producing 50% inhibition (KiM5) of the chemiluminescent response of neutrophils, stimulated with fMLP+CB was 16-5 (6) FM (mean (SE) n=5, Fig. 2 ). The Ki50 for 5ASA was 3-6 (1-8) FtM (n=6, Fig. 2 Table) .
EFFECT ON OXYGEN CONSUMPTION BY NEUTROPHI LS
5-amino-salicylic acid had no significant inhibitory effect on the rate of oxygen consumption by neutrophils stimulated with fMLP+CB (Fig. 3) . The uninhibited stimulated rate was 0-0381 (0.025) nmol/sec/105 neutrophils, and in cells pretreated with 5ASA the rate was 0.0349 (0.02) nmol/sec/106 neutrophils (mean (SD), mean inhibition 8.4%). Sulphasalazine also failed to significantly inhibit oxygen consumption by stimulated neutrophils (Fig. 3) . The uninhibited and SAL pre-treated cells consuming oxygen at 0-0363 (0.022) nmol/sec/100 neutrophils, and 0-032 (0.021) nmol/sec/10' neutrophils (mean inhibition 11.9%) respectively.
Discussion
In this paper, we have shown that sulphasalazine and its active metabolite 5ASA, have a profound inhibitory effect on the luminol dependent chemiluminescent response of neutrophils after chemotactic stimulation, which was not mirrored by similar inhibition of superoxide production or oxygen consumption. Inhibition may result from interference at one or more sites in the chain of events which result in the production of reactive oxygen metabolites by stimulated neutrophils (Fig. 4) . These include: (a) blocking of the stimulus receptor on the cell membrane, (b) direct, blanket inhibition of the cell, (c) inhibition of the oxidase system, or (d) extracellularly, by scavenging released oxygen metabolites.
Sulphasalazine and SASA have both been shown to inhibit the chemotactic activity of neutrophils.' It has been suggested that these drugs inhibit neutrophil activity by blocking binding of fMLP to its receptor.'' The inhibition of luminol dependent chemiluminesence by SAL and 5ASA showed here, however, is unlikely to be a consequence of blocking the fMLP receptor, because the drugs produced little inhibition of oxygen consumption during the respiratory burst of neutrophils stimulated with fMLP+CB.
A direct non-specific effect of the drugs on the neutrophil was also excluded as there was little inhibition of PMA stimulated luminol-dependent chemiluminesence and oxygen consumption was not affected by sulphasalazine and 5ASA. This also excludes the possibility that the drugs acted by inhibition of the oxidase enzyme system (site c, Fig. 4 ).
An extracellular site of action (d, Fig. 4 ) therefore remains the only possibility. Previous authors have shown that sulphasalazine and its metabolites react variably with superoxide, hydrogen peroxide and hydroxyl radicals in cell-free systems.-`" Our results suggest that superoxide is not the major metabolite being scavenged, as 5ASA only inhibited superoxide production by neutrophils by 35% and sulphasalazine by 7-9%. Luminol dependent chemiluminesence was almost totally inhibited by similar concentrations of 5ASA, which would imply that a secondary radical, formed from superoxide, is being scavenged.
Triggering of luminol dependent chemiluminesence by neutrophils depends on release of myeloperoxidase and hydrogen peroxide, conditions which generate hypochlorite.' '8 Sulphasalazine and 5ASA do not inhibit myeloperoxidase (unpublished observations) therefore, the inhibition of luminoldependent chemiluminesence, may be the result of hypochlorite scavenging by sulphasalazine and 5ASA. Auroma et al' showed that 5ASA scavenges hypochlorite in a cell free system and our similar conclusion, based on experiments on neutrophils, strengthens the hypothesis that 5ASA acts by scavenging hypochlorite in inflamed tissue.
Oxygen radical production by fMLP+CB stimulated neutrophils involves exocytosis of myloperoxidase, whereas little myeloperoxidase is released after stimulation with PMA.2' Thus hypochlorite formation occurs extracellularly after fMLP stimulation and intracellularly after PMA. The differential effect of 5ASA and SAL on luminol dependent chemiluminesence stimulated by fMLP and PMA may reflect a difference in the availability of these drugs at extracellular and intracellular sites, or differences in the generation of the peroxidasedependent metabolite.
After oral ingestion, one third of the dose of 5ASA is recovered in urine, mostly as the acetylated 
